Fuda Cancer Hospital Pancreatic Cancer Treatment: Options, Evidence & Case Fit
FUDA is internationally visible for minimally invasive pancreatic-cancer procedures, especially NanoKnife / irreversible electroporation (IRE), cryoablation and image-guided interventional treatment. The correct starting point, however, is not a technology. It is resectability, stage, performance status, pathology, molecular profile and prior systemic therapy.
Quick answer: FUDA can be a reasonable center to review when the clinical question is whether a
local interventional treatment adds value for an unresectable or otherwise difficult pancreatic tumor.
It should not replace a high-volume pancreatic multidisciplinary assessment. For resectable or borderline-resectable
disease, surgery and systemic therapy remain central. For locally advanced disease, systemic therapy is the backbone;
IRE remains selective rather than routine. For metastatic disease, local ablation does not replace whole-body treatment.
✓ Standard care before technology
✓ IRE evidence separated from FUDA marketing
✓ Historical cryo data labeled historical
✓ Metastatic disease treated as systemic disease
Pancreatic Cancer Stage Router: Where FUDA Fits — and Where It May Not
| Clinical situation | Standard-care anchor | FUDA-specific question | Decision rule |
|---|---|---|---|
| Resectable | High-volume pancreatic surgery + perioperative systemic therapy planning | Usually not “Which ablation?” | Compare a specialist pancreatic surgical center before choosing a local ablation strategy. |
| Borderline resectable | Systemic therapy first, restaging, then surgical reassessment when appropriate | Whether any local technique adds value after induction treatment | Do not use IRE or cryo as a shortcut around resectability review. |
| Locally advanced / stage III | Systemic therapy backbone; selected patients may receive chemoradiation or SBRT | Whether IRE / another local procedure is reasonable after systemic therapy and restaging | This is FUDA’s strongest pancreatic interventional-fit question, but evidence remains mixed. |
| Metastatic / stage IV | Systemic therapy + supportive / symptom-directed care | Whether a local procedure has a palliative or highly selected disease-control role | Ablating the pancreatic mass does not treat liver, lung, peritoneal or other metastatic disease. |
| Local recurrence after prior treatment | Restaging + review of prior surgery/radiation/systemic therapy | Whether IRE, SBRT, re-resection or another local method is technically feasible | Requires current imaging and a center able to compare multiple local options. |
This router follows the 2026 NCCN patient framework: resectability and performance status drive the pathway, while systemic therapy is the most common treatment for advanced pancreatic cancer. Clinical trials are preferred when appropriate.
What Standard Pancreatic-Cancer Care Must Be Checked Before FUDA Ablation
Can the tumor be removed safely?
Resectable, borderline-resectable and locally advanced disease are different treatment problems. Vessel involvement, metastatic spread and surgical anatomy should be reviewed by an experienced pancreatic team.
What has already been given, and did the cancer respond?
For locally advanced and metastatic disease, chemotherapy / systemic therapy is central. A local intervention should be interpreted in the context of response, stability or progression on systemic treatment.
Is chemoradiation or SBRT a reasonable comparator?
NCCN’s 2026 patient guide includes chemoradiation or SBRT for selected locally advanced cases, often after a period of chemotherapy. Any IRE proposal should be compared with these options when clinically relevant.
Does molecular testing change systemic treatment?
Germline and tumor molecular testing can identify a minority of patients with actionable alterations or immunotherapy-sensitive biology. A local procedure should not distract from biomarker-directed systemic decisions.
What FUDA Currently Offers for Pancreatic Cancer
FUDA’s 2026 patient-facing material highlights two minimally invasive methods for pancreatic cancer: NanoKnife / IRE and cryoablation. Its broader treatment directory also includes brachytherapy / iodine-125 seed implantation, vascular intervention, chemotherapy and other oncology modalities.
NanoKnife / IRE
FUDA actively promotes IRE for difficult pancreatic tumors and continues presenting pancreatic IRE at 2026 international meetings. This establishes current program activity, not proof that IRE improves survival over standard care.
Cryoablation
FUDA has a substantial historical pancreatic cryosurgery publication record and still presents cryo as a pancreatic option. The strongest pancreatic cryo data from FUDA are old institutional cohorts, so they should not be projected directly onto 2026 outcomes.
Iodine-125 / brachytherapy
FUDA historically combined iodine-125 seeds with cryosurgery in unresectable and advanced pancreatic cancer. This is not a default modern pancreatic-cancer pathway; ask exactly why brachytherapy is being proposed now.
NanoKnife / IRE for Pancreatic Cancer: What the Evidence Actually Shows
Selected stage III and recurrent disease
A modified-Delphi consensus from 11 experienced IRE experts stated that pancreatic IRE should be considered for stage III pancreatic cancer and for inoperable recurrent disease after previous local treatment. The same paper emphasizes standardized selection, technique and follow-up.
IRE did not beat SABR after FOLFIRINOX
In CROSSFIRE, 68 patients with stage III locally advanced pancreatic cancer were randomized after FOLFIRINOX to MRI-guided SABR or CT-guided percutaneous IRE. Median overall survival from randomization was 16.1 months with SABR and 12.5 months with IRE; the trial stopped early for futility and found no survival difference.
38 IRE studies · 2,245 patients
The largest recent systematic review reported median overall survival of 17.2 months across IRE studies, with adverse events in 36% of patients and about half of those events severe. The authors’ global analysis argued against routine IRE use in pancreatic ductal adenocarcinoma.
IRE is a selective local-treatment question
These data do not mean that no patient should receive IRE. They mean that a FUDA IRE proposal should be justified by stage, anatomy, prior therapy, performance status, alternatives and treatment goal — not by the technology name.
FUDA’s Pancreatic IRE Research Footprint
| Study / publication | What it evaluated | Status | How to interpret it |
|---|---|---|---|
| NCT02981719 | Gemcitabine + IRE versus IRE alone for locally advanced pancreatic cancer | Completed; FUDA-sponsored; last registry update 2021 | Historical institutional research, not a current recruiting pathway. |
| PMID 33344547 | FUDA-affiliated study of concurrent gemcitabine + IRE versus gemcitabine alone | Published 2020 | Supports a real FUDA pancreatic-IRE research program; does not override newer randomized/systematic evidence. |
| PMID 37691923 | IRE + chemotherapy + PD-1/PD-L1 blockade in locally advanced pancreatic cancer | Published 2023 | Signals ongoing combination-therapy research; selection bias and non-definitive design remain important. |
| PMID 41024805 | Hypertension and tachycardia during pancreatic IRE | Published 2025 | Useful safety evidence that electrical ablation has procedure-specific physiologic risks. |
What Is New at FUDA in 2026?
FUDA highlights NanoKnife and cryo
FUDA’s patient-facing “New Option for Pancreatic Cancer” page highlights NanoKnife and cryoablation as minimally invasive pancreatic options and explicitly says professional medical consultation is essential.
IRE synchronized with systemic treatment
At APSCVIR / ISMIO, FUDA reported presentations on NanoKnife combined with chemotherapy and immunotherapy for unresectable pancreatic cancer. This is a current academic-program signal, not independent proof of benefit.
Single-needle IRE under local anesthesia
FUDA published a case story describing an 81-year-old patient treated with a newer single-needle bipolar IRE system under local anesthesia. ParkMega treats this as provider-reported technology-watch material until device status, reproducibility and independent outcome data are stronger.
FUDA Pancreatic Cryoablation: Why the Evidence Must Be Dated
Feasibility / safety cohort
FUDA investigators retrospectively reviewed percutaneous US/CT-guided pancreatic cryoablation. The study documents institutional technical experience, but it comes from an older treatment era and is not a modern comparative trial.
Metastatic pancreatic cancer cohort
FUDA retrospectively analyzed 106 patients across cryoimmunotherapy, cryotherapy, immunotherapy and chemotherapy groups. These results are hypothesis-generating historical evidence, not a basis for promising current survival outcomes.
Cryosurgery + iodine-125 seeds
FUDA authors described combined cryosurgery and iodine-125 brachytherapy in pancreatic cancer. It supports the center’s historical experience with combined local techniques, not current guideline status.
Ask what modern comparator was considered
If FUDA proposes cryo in 2026, ask whether a pancreas specialist compared surgery, systemic treatment, SBRT, IRE and symptom-directed approaches using the patient’s current imaging and stage.
Stage IV Pancreatic Cancer: Why Local Treatment Needs Extra Scrutiny
Metastatic pancreatic cancer is a systemic disease. Cryoablation, IRE or iodine-125 can only act on
specific local targets. They do not treat invisible micrometastatic disease or all known metastatic sites.
Reasonable local-treatment goals may include
- Pain or symptom relief in selected anatomy
- Control of a dominant local lesion
- Highly selected oligometastatic / oligoprogressive scenarios
- A local component inside a broader systemic-treatment plan
Red flags
- “We can ablate the pancreas, therefore the cancer is controlled”
- Stopping effective systemic therapy without a clear medical reason
- No discussion of liver / lung / peritoneal metastases
- Using an old FUDA cohort as a current survival guarantee
When FUDA May Be Worth Reviewing
Locally advanced pancreatic cancer after systemic therapy
The disease is nonmetastatic, surgery is not currently feasible, and the team is deciding whether a local treatment adds value.
A technically difficult local recurrence
Prior surgery or radiation limits standard local options and the patient needs comparison of IRE, SBRT, re-resection or another intervention.
A specific interventional-oncology question
The patient is not simply asking “Where is the best hospital?” but whether IRE, cryo or another image-guided method is technically relevant.
A second opinion on a FUDA treatment proposal
The patient already has a quote or plan and needs the stage, evidence, alternatives, doctor and cost assumptions checked before travel.
When to Compare FUDA With Another China Pancreatic Center
Resectable or potentially convertible disease
When Whipple surgery, distal pancreatectomy, vascular reconstruction or conversion surgery is a realistic possibility, compare FUDA with a high-volume academic pancreatic surgical center before choosing ablation.
Biomarker-driven or trial-driven decisions
A major academic cancer center may have broader pancreatic medical-oncology, molecular-tumor-board and clinical-trial infrastructure. Local ablation capability should not be the only reason to choose a hospital.
Pathology or staging still uncertain
Before traveling for an ablation, confirm pancreatic adenocarcinoma versus neuroendocrine tumor, cystic neoplasm, metastasis to the pancreas or another diagnosis that follows a different treatment pathway.
One center says surgery; another says IRE
That disagreement is exactly when a second high-volume multidisciplinary opinion is useful before paying or traveling.
Which FUDA Doctors Are Most Relevant to the Pancreatic Case Question?
Prof. Niu Lizhi
FUDA’s current material repeatedly associates Niu Lizhi with pancreatic IRE and complex tumor ablation, including 2026 WATA and APSCVIR / ISMIO presentations. Confirm current appointment and procedure responsibility for the actual case.
Dr. Liu Shupeng
FUDA’s profile lists IRE, cryoablation and other minimally invasive techniques. His broader interventional-oncology experience may be relevant when the question is local treatment rather than pancreatic surgery.
For a full doctor map, see Fuda Cancer Hospital Doctors. A named doctor on a website is not the same as confirmed review or procedure availability.
What Records Should Be Sent for a FUDA Pancreatic Cancer Review?
Minimum oncology file
- Pathology / biopsy report
- Exact histology and grade when available
- Latest pancreas-protocol CT and/or MRI
- Chest imaging and metastatic staging
- PET-CT if already performed
- DICOM imaging files, not only screenshots
- CA 19-9 trend and relevant blood tests
Treatment / decision file
- Current resectability assessment
- All chemotherapy regimens, dates and response
- Previous radiation / SBRT
- Previous pancreatic or biliary surgery / stents
- Germline and tumor molecular testing
- Performance status and major comorbidities
- Any FUDA quote or proposed procedure
Questions to Ask FUDA Before Accepting a Pancreatic Treatment Plan
Is the cancer resectable, borderline resectable, locally advanced or metastatic?
Ask FUDA to state the category and why, including vessel involvement and distant disease.
What is the treatment goal?
Curative-intent resection, conversion to surgery, durable local control, palliation and symptom relief are different endpoints.
Why IRE, cryo or iodine-125 instead of the main alternatives?
Ask for the rationale versus surgery, systemic therapy, SBRT / chemoradiation or supportive care.
What systemic therapy continues before and after the local procedure?
For locally advanced or metastatic disease, the local plan should fit into a whole-body treatment strategy.
Who will perform the procedure and which device / technique?
For IRE, clarify conventional multi-electrode NanoKnife versus newer single-needle / bipolar technology and the evidence supporting that platform.
What is the written cost and complication plan?
Request procedure, probes/seeds, imaging, anesthesia, medicines, room, ICU if needed, expected stay and management of major complications.
How Much Does FUDA Pancreatic Cancer Treatment Cost?
There is no responsible single “FUDA pancreatic cancer price.” A plan can range from medical review and systemic therapy
to IRE, cryoablation, brachytherapy, embolization / infusion, inpatient care and combinations of several methods.
Cost should therefore follow the medical plan, not precede it.
Use the Fuda Cancer Hospital Cost guide to check whether the estimate includes procedure consumables, anesthesia, imaging, medicines, room, ICU, pathology, follow-up and likely additional treatment.
International-Patient Access: Review the File Before Booking Travel
FUDA’s international-patient pathway starts with medical records. For pancreatic cancer this is especially important
because a travel decision can change completely if the tumor is resectable, metastatic, progressing on current therapy
or technically unsuitable for the proposed local procedure.
See Fuda Cancer Hospital for International Patients for records review, visa support, airport pickup, language and admission questions.
How ParkMega Reviews a FUDA Pancreatic Cancer Case
Stage first. Then compare FUDA’s local-treatment proposal.
Send pathology, recent imaging, systemic-treatment history and any FUDA proposal. We can separate the standard-care backbone from the optional local procedure, identify evidence gaps, and flag when another Chinese pancreatic center should review the same file before travel.
Related FUDA and China Cancer Guides
Frequently Asked Questions
Direct answers about FUDA pancreatic cancer treatment, NanoKnife, cryoablation, stage, evidence, doctors and costs.
Does Fuda Cancer Hospital treat pancreatic cancer?
Yes. FUDA publishes a current pancreatic-cancer program with minimally invasive options including NanoKnife/IRE and cryoablation, and its broader oncology services include systemic and interventional treatments. Suitability depends on stage, resectability, anatomy, prior therapy and the exact treatment goal.
Is FUDA a good option for resectable pancreatic cancer?
A resectable pancreatic cancer case should first be reviewed by a high-volume pancreatic surgical team because surgery remains central when complete resection is feasible. FUDA may still provide a second opinion, but a local ablation should not replace surgical assessment simply because it is less invasive.
When might FUDA NanoKnife be considered for pancreatic cancer?
The strongest case-fit question is usually selected locally advanced stage III disease or inoperable local recurrence after appropriate staging and systemic therapy. A 2024 expert consensus supports considering IRE in those settings, but a 2025 systematic review argued against routine IRE use in pancreatic ductal adenocarcinoma.
Did a randomized trial prove NanoKnife is better than radiation?
No. The 2024 CROSSFIRE randomized phase 2 trial compared MRI-guided SABR with CT-guided percutaneous IRE after FOLFIRINOX in stage III pancreatic cancer. It found no overall-survival difference and stopped early for futility.
Does FUDA have its own pancreatic IRE research?
Yes. FUDA sponsored NCT02981719 and has published studies on IRE with chemotherapy and with PD-1/PD-L1 blockade. These studies document a real institutional research program, but current treatment decisions should still consider newer independent randomized and systematic evidence.
Does FUDA use cryoablation for pancreatic cancer?
FUDA has published pancreatic cryoablation cohorts and still presents cryoablation as a pancreatic option. However, the main FUDA pancreatic cryo publications are from roughly 2012-2013, so they should be treated as historical institutional evidence rather than current standard-of-care proof.
What is iodine-125 seed implantation for pancreatic cancer?
Iodine-125 seed implantation is interstitial brachytherapy in which radioactive sources are placed in or near a tumor. FUDA historically combined it with cryosurgery in unresectable or advanced pancreatic cancer. If proposed today, ask why brachytherapy is preferred over current surgical, systemic and radiation alternatives.
Can local ablation cure stage IV pancreatic cancer?
Local ablation treats specific lesions and does not treat cancer throughout the body. Stage IV pancreatic cancer is systemic disease, so systemic treatment and supportive care remain central. A local procedure may have a palliative or highly selected disease-control role, but it should not be presented as whole-body disease eradication.
What is FUDA’s new single-needle NanoKnife?
In August 2026 FUDA published a case story describing a single-needle bipolar IRE procedure under local anesthesia. ParkMega treats this as provider-reported technology-watch material until the exact device status, independent validation, reproducibility and longer-term outcomes are better established.
Which FUDA doctor is associated with pancreatic NanoKnife?
FUDA repeatedly associates Niu Lizhi with pancreatic IRE and complex ablation, including 2026 international presentations. Liu Shupeng is also linked to interventional oncology and IRE in FUDA materials. Current doctor availability and who would actually perform the procedure must be confirmed for the specific patient.
What records should I send for a FUDA pancreatic cancer review?
Send pathology, pancreas-protocol CT or MRI, chest and metastatic staging, DICOM files when available, CA 19-9 trend, prior chemotherapy and response, prior radiation, surgical history, biliary stent information, molecular testing, performance status and any existing FUDA proposal.
How much does pancreatic cancer treatment at FUDA cost?
There is no single reliable package price. Cost depends on whether the plan involves IRE, cryoablation, brachytherapy, systemic treatment, imaging, anesthesia, inpatient care and additional procedures. Request a written itemized estimate only after FUDA reviews the medical file.
Sources and Evidence
- NCCN Guidelines for Patients: Pancreatic Cancer, Version 2.2026. Current public patient guideline for resectability, locally advanced / metastatic treatment, systemic therapy and radiation options. NCCN patient guideline.
- FUDA — New Option for Pancreatic Cancer, February 2026. Current provider page highlighting NanoKnife and cryoablation. FUDA page.
- FUDA — APSCVIR / ISMIO, June 2026. Hospital-reported pancreatic IRE + chemotherapy / immunotherapy activity. FUDA report.
- FUDA — WATA 2026. Hospital-reported NanoKnife application for liver and pancreatic tumors under combined ultrasound / CT guidance. FUDA report.
- FUDA — Single-needle IRE case story, August 2026. Provider-reported newer bipolar / local-anesthesia technique; treated as technology-watch material. FUDA story.
- Vos et al., 2024 — PMID 38993594. Modified-Delphi consensus on pancreatic IRE patient selection, contraindications, technique and follow-up. PubMed.
- Timmer et al., 2024 — PMID 38513683. CROSSFIRE randomized phase 2 trial comparing SABR with IRE after FOLFIRINOX in stage III locally advanced pancreatic cancer. PubMed.
- Marcellier et al., 2025 — PMID 40879173. Systematic review of electroporation for pancreatic ductal adenocarcinoma; 38 IRE studies / 2,245 patients. PubMed.
- ClinicalTrials.gov NCT02981719. Completed FUDA-sponsored pancreatic IRE trial; not a current recruitment route. ClinicalTrials.gov.
- Ma et al., 2020 — PMID 33344547. FUDA-affiliated pancreatic IRE / gemcitabine study. PubMed.
- Ma et al., 2023 — PMID 37691923. FUDA-affiliated IRE + chemotherapy + PD-1 / PD-L1 blockade study. PubMed.
- Li et al., 2025 — PMID 41024805. FUDA-affiliated analysis of hypertension / tachycardia during pancreatic IRE. PubMed.
- Niu et al., 2012 — PMID 22960266. Historical FUDA pancreatic cryoablation feasibility / safety cohort. PubMed.
- Niu et al., 2013 — PMID 23899940. Historical FUDA metastatic pancreatic cryo / immunotherapy cohort. PubMed.
- Xu et al., 2013 — PMID 25083464. Historical FUDA pancreatic cryosurgery + iodine-125 brachytherapy report. PubMed.
Evidence rule: FUDA sources establish what the hospital currently says it offers and reports doing. Independent guidelines, randomized trials and systematic reviews are used to judge where those procedures fit relative to modern pancreatic-cancer care.
Medical note: This page does not diagnose pancreatic cancer or recommend a specific procedure. A treating oncology / pancreatic multidisciplinary team should review the case before travel.
Start With Stage and Resectability — Then Evaluate FUDA’s Proposal
Send pathology, pancreas imaging, metastatic staging, prior systemic therapy and any FUDA quote. We can structure the questions around surgery, systemic treatment, IRE, cryo, brachytherapy, evidence level, doctor / department and total cost.
✓ Stage before technology
✓ Resectability checked first
✓ IRE kept selective, not routine
✓ Stage IV framed as systemic disease
Review your pancreatic cancer case for Fuda
Start with pathology, resectability, stage, recent imaging and prior systemic therapy. The goal is to separate standard care from optional local procedures and confirm whether Fuda is the right fit before travel.